These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 32145228)

  • 21. Topical amphotericin B in ultradeformable liposomes: Formulation, skin penetration study, antifungal and antileishmanial activity in vitro.
    Perez AP; Altube MJ; Schilrreff P; Apezteguia G; Celes FS; Zacchino S; de Oliveira CI; Romero EL; Morilla MJ
    Colloids Surf B Biointerfaces; 2016 Mar; 139():190-8. PubMed ID: 26709977
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacious treatment of experimental leishmaniasis with amphotericin B-arabinogalactan water-soluble derivatives.
    Golenser J; Frankenburg S; Ehrenfreund T; Domb AJ
    Antimicrob Agents Chemother; 1999 Sep; 43(9):2209-14. PubMed ID: 10471566
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Amphotericin B and its new derivatives - mode of action.
    Baginski M; Czub J
    Curr Drug Metab; 2009 Jun; 10(5):459-69. PubMed ID: 19689243
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro and in vivo antileishmanial activity of a fluoroquinoline derivate against Leishmania infantum and Leishmania amazonensis species.
    Tavares GSV; Mendonça DVC; Lage DP; Antinarelli LMR; Soyer TG; Senna AJS; Matos GF; Dias DS; Ribeiro PAF; Batista JPT; Poletto JM; Brandão GC; Chávez-Fumagalli MA; Pereira GR; Coimbra ES; Coelho EAF
    Acta Trop; 2019 Mar; 191():29-37. PubMed ID: 30586571
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New formulations and derivatives of amphotericin B for treatment of leishmaniasis.
    Golenser J; Domb A
    Mini Rev Med Chem; 2006 Feb; 6(2):153-62. PubMed ID: 16472184
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development of mannose-anchored thiolated amphotericin B nanocarriers for treatment of visceral leishmaniasis.
    Shahnaz G; Edagwa BJ; McMillan J; Akhtar S; Raza A; Qureshi NA; Yasinzai M; Gendelman HE
    Nanomedicine (Lond); 2017 Jan; 12(2):99-115. PubMed ID: 27879160
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In-vitro and in-vivo antileishmanial activity of inexpensive Amphotericin B formulations: Heated Amphotericin B and Amphotericin B-loaded microemulsion.
    Rochelle do Vale Morais A; Silva AL; Cojean S; Balaraman K; Bories C; Pomel S; Barratt G; do Egito EST; Loiseau PM
    Exp Parasitol; 2018 Sep; 192():85-92. PubMed ID: 30075233
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterization of the colloidal properties, in vitro antifungal activity, antileishmanial activity and toxicity in mice of a di-stigma-steryl-hemi-succinoyl-glycero-phosphocholine liposome-intercalated amphotericin B.
    Iman M; Huang Z; Szoka FC; Jaafari MR
    Int J Pharm; 2011 Apr; 408(1-2):163-72. PubMed ID: 21277963
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vivo antileishmanial efficacy of a naphthoquinone derivate incorporated into a Pluronic
    Mendonça DVC; Tavares GSV; Lage DP; Soyer TG; Carvalho LM; Dias DS; Ribeiro PAF; Ottoni FM; Antinarelli LMR; Vale DL; Ludolf F; Duarte MC; Coimbra ES; Chávez-Fumagalli MA; Roatt BM; Menezes-Souza D; Barichello JM; Alves RJ; Coelho EAF
    Biomed Pharmacother; 2019 Jan; 109():779-787. PubMed ID: 30551531
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cholesterol improves stability of amphotericin B nanoemulsion: promising use in the treatment of cutaneous leishmaniasis.
    Mansur-Alves I; Lima BLF; Santos TT; Araújo NF; Frézard F; Islam A; de Barros AL; Dos Santos DC; Fernandes C; Ferreira LA; Aguiar MM
    Nanomedicine (Lond); 2022 Aug; 17(18):1237-1251. PubMed ID: 36189757
    [No Abstract]   [Full Text] [Related]  

  • 31. Nanoemulsions Loaded with Amphotericin B: Development, Characterization and Leishmanicidal Activity.
    Araújo GMF; Barros ARA; Oshiro-Junior JA; Soares LF; da Rocha LG; de Lima ÁAN; da Silva JA; Converti A; Damasceno BPGL
    Curr Pharm Des; 2019; 25(14):1616-1622. PubMed ID: 31298163
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Amphotericin B-loaded nanoparticles for local treatment of cutaneous leishmaniasis.
    Abu Ammar A; Nasereddin A; Ereqat S; Dan-Goor M; Jaffe CL; Zussman E; Abdeen Z
    Drug Deliv Transl Res; 2019 Feb; 9(1):76-84. PubMed ID: 30484256
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of low doses of amphotericin B plus allicin against experimental visceral leishmaniasis.
    Corral MJ; Serrano DR; Moreno I; Torrado JJ; Domínguez M; Alunda JM
    J Antimicrob Chemother; 2014 Dec; 69(12):3268-74. PubMed ID: 25096077
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biological activity of Morita-Baylis-Hillman adduct homodimers in L. infantum and L. amazonensis: anti-Leishmania activity and cytotoxicity.
    da Câmara Rocha J; da Franca Rodrigues KA; do Nascimento Néris PL; da Silva LV; Almeida FS; Lima VS; Peixoto RF; da Câmara Rocha J; de Azevedo FLAA; Veras RC; de Medeiros IA; da Silva WAV; Lima-Junior CG; de Almeida Vasconcellos MLA; do Amaral IPG; de Oliveira MR; de Souza Lima Keesen T
    Parasitol Res; 2019 Oct; 118(10):3067-3076. PubMed ID: 31392413
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Liposomal formulations in the pharmacological treatment of leishmaniasis: a review.
    Ortega V; Giorgio S; de Paula E
    J Liposome Res; 2017 Sep; 27(3):234-248. PubMed ID: 28874072
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of antileishmanial lipid nanocomplexes.
    Pham TT; Gueutin C; Cheron M; Abreu S; Chaminade P; Loiseau PM; Barratt G
    Biochimie; 2014 Dec; 107 Pt A():143-53. PubMed ID: 24952352
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Alginate-amphotericin B nanocomplexes covered by nanocrystals from bacterial cellulose: physico-chemical characterization and in vitro toxicity.
    Soeiro VS; Silva-Carvalho R; Martins D; Parpot P; Grotto D; Chaud MV; da Gama FMP; Jozala AF
    Sci Rep; 2021 Dec; 11(1):23944. PubMed ID: 34907234
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of lapachol on treatment of cutaneous and visceral leishmaniasis.
    Araújo IAC; de Paula RC; Alves CL; Faria KF; Oliveira MM; Mendes GG; Dias EMFA; Ribeiro RR; Oliveira AB; Silva SMD
    Exp Parasitol; 2019 Apr; 199():67-73. PubMed ID: 30797783
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro activity of amphotericin B cochleates against Leishmania chagasi.
    Sesana AM; Monti-Rocha R; Vinhas SA; Morais CG; Dietze R; Lemos EM
    Mem Inst Oswaldo Cruz; 2011 Mar; 106(2):251-3. PubMed ID: 21537689
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Amphotericin-B colloidal dispersion. A review of its use against systemic fungal infections and visceral leishmaniasis.
    Brogden RN; Goa KL; Coukell AJ
    Drugs; 1998 Sep; 56(3):365-83. PubMed ID: 9777313
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.